- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07944261
Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits (MILD-EFFECT)
Low-Dose Recombinant Human Tenecteplase Tissue-Type Plasminogen Activator for Injection in Acute Minor Ischemic Stroke With Disabling Deficits: The MILD-EFFECT Multicenter Randomized Controlled Trial
This study will compare two doses of a clot-dissolving medicine called tenecteplase (TNK), specifically recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA), in adults with a mild ischemic stroke that causes disabling symptoms. An ischemic stroke occurs when a blood clot blocks blood flow to the brain. Even a mild stroke can cause problems that prevent a person from carrying out basic daily activities or returning to work.
The main question is whether a lower dose of rhTNK-tPA helps patients recover nearly as well as the standard dose, within a predefined acceptable difference. The study will also compare bleeding and other side effects between the two doses.
Up to 1,324 participants at multiple hospitals will be randomly assigned to receive either the lower dose (0.18 mg/kg, up to 16 mg) or the standard dose (0.25 mg/kg, up to 25 mg). Each participant will receive one injection into a vein within 4.5 hours of stroke onset, along with usual stroke care. Participants and treating doctors will know which dose is given, but the assessors evaluating recovery will not.
Participants will be followed for approximately 90 days. Researchers will assess recovery, ability to carry out daily activities, quality of life, bleeding, and other medical problems. The main outcome is the proportion of participants who have no symptoms or no significant disability at about 90 days after treatment.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: QinJian Sun
- Número de teléfono: 86-0531-68773275
- Correo electrónico: sqj1210@163.com
Ubicaciones de estudio
-
-
Shandong
-
Jinan, Shandong, Porcelana, 250021
- Reclutamiento
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
-
Contacto:
- Qinjian Sun, MD
- Número de teléfono: +86-0531-68773275
- Correo electrónico: sqj1210@163.com
-
Investigador principal:
- QinJian Sun
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥18 years.
- Clinical diagnosis of acute ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) score ≤5.
- Presence of clearly disabling neurological deficits that persist and prevent the participant from independently performing at least one basic activity of daily living (including bathing, dressing, walking, toileting, personal hygiene, and eating) and/or returning to their previous work.
- Time from stroke onset to treatment <4.5 hours, with onset defined as the time of symptom onset or the last known well time.
- Pre-stroke modified Rankin Scale (mRS) score ≤1.
- Voluntary participation and written informed consent provided by the participant or their legally authorized representative.
Exclusion Criteria:
- Intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma.
- NIHSS item 1a score >2.
- Planned endovascular treatment before randomization.
- History of intracranial hemorrhage, or presence of an intra-axial intracranial tumor, giant intracranial aneurysm, or arteriovenous malformation.
- History of stroke within the preceding 3 months.
- Recent anticoagulant treatment with coagulation parameters that do not meet the safety requirements for thrombolysis.
- Active internal bleeding or an acute bleeding tendency, including a platelet count <100 × 10⁹/L.
- Concomitant bacterial endocarditis, pericarditis, acute pancreatitis, or other severe, difficult-to-control infections.
- History of major trauma (e.g., severe head injury within the preceding 3 months), surgery or invasive procedures (e.g., intracranial or spinal canal surgery within the preceding 3 months, major surgery within the preceding 2 weeks, or arterial puncture at a site not amenable to compression within the preceding week), or bleeding (e.g., gastrointestinal or urinary tract bleeding within the preceding 3 weeks).
- Persistent uncontrolled hypertension despite active antihypertensive treatment: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg.
- Blood glucose <2.8 mmol/L or >22.22 mmol/L. Eligibility may be reassessed after correction of blood glucose if clearly disabling neurological deficits associated with minor stroke persist and the participant meets the diagnostic criteria for acute ischemic stroke and the eligibility requirements for intravenous thrombolysis.
- Postictal paresis (Todd's paresis), or other neurological or psychiatric conditions resulting in inability or unwillingness to cooperate.
- Known allergy to the active ingredient rhTNK-tPA or any of its excipients.
- Current participation in another interventional medical device or drug study, or completion of participation in such a study less than 30 days previously.
- Pregnancy, breastfeeding, or unwillingness of a female participant to use effective contraception during the trial.
- Other serious diseases associated with a life expectancy of less than 6 months.
- Any other condition that, in the investigator's judgment, may substantially increase bleeding risk, interfere with study assessments, or render the participant unsuitable for the trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Low-Dose Tenecteplase (rhTNK-tPA)
Participants will receive rhTNK-tPA at 0.18 mg/kg, with a maximum dose of 16 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines. |
Tenecteplase (rhTNK-tPA) will be administered at 0.18 mg/kg, with a maximum dose of 16 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Otros nombres:
|
|
Comparador activo: Standard-Dose Tenecteplase (rhTNK-tPA)
Participants will receive rhTNK-tPA at 0.25 mg/kg, with a maximum dose of 25 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines. |
Tenecteplase (rhTNK-tPA) will be administered at 0.25 mg/kg, with a maximum dose of 25 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-1
Periodo de tiempo: 90 ± 7 days after randomization
|
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-1 indicates no significant disability. |
90 ± 7 days after randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-2
Periodo de tiempo: 90 ± 7 days after randomization
|
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-2 indicates functional independence. |
90 ± 7 days after randomization
|
|
Distribution of Modified Rankin Scale (mRS) Scores
Periodo de tiempo: 90 ± 7 days after randomization
|
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. The distribution across all seven categories (0-6) will be assessed. |
90 ± 7 days after randomization
|
|
Proportion of Participants With a National Institutes of Health Stroke Scale (NIHSS) Score of 0-1
Periodo de tiempo: 22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first
|
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. An NIHSS score of 0-1 indicates no or minimal neurological deficits. |
22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first
|
|
Proportion of Participants With an Increase From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
Periodo de tiempo: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
|
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological worsening is defined as an increase of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline. |
Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
|
|
Proportion of Participants With a Decrease From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
Periodo de tiempo: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
|
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological improvement is defined as a decrease of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline. |
Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
|
|
Proportion of Participants With a COSMOS score Grade of 0-1
Periodo de tiempo: 90 ± 7 days after randomization
|
The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence or worse), with higher scores indicating worse outcomes. The proportion of participants with a COSMOS grade of 0-1 will be assessed. |
90 ± 7 days after randomization
|
|
COSMOS Score
Periodo de tiempo: 90 ± 7 days after randomization
|
The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence for an instrumental or basic activity of daily living or worse), with higher scores indicating worse outcomes. The distribution of COSMOS grades from 0 to 6 at 90 days will be assessed. |
90 ± 7 days after randomization
|
|
Health-Related Quality of Life Assessed by EQ-5D-3L and EQ VAS
Periodo de tiempo: 90 ± 7 days after randomization
|
The EuroQol Five-Dimension Three-Level Questionnaire (EQ-5D-3L) assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels, ranging from 1 (no problems) to 3 (extreme problems or inability to perform the activity), with higher levels indicating worse health status. The accompanying EuroQol Visual Analogue Scale (EQ VAS) assesses self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better health status. |
90 ± 7 days after randomization
|
|
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 36 Hours
Periodo de tiempo: Within 36 hours after study drug administration
|
Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death. |
Within 36 hours after study drug administration
|
|
Incidence of Any Intracranial Hemorrhage Within 36 Hours
Periodo de tiempo: Within 36 hours after study drug administration
|
Any intracranial hemorrhage is defined as the presence of intracranial bleeding detected by brain computed tomography (CT) or magnetic resonance imaging (MRI), regardless of whether neurological deterioration or clinical symptoms are present. Both symptomatic and asymptomatic intracranial hemorrhages are included. |
Within 36 hours after study drug administration
|
|
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 7 Days
Periodo de tiempo: Within 7 days after study drug administration
|
Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death. Events occurring within 7 days after study drug administration will be assessed. |
Within 7 days after study drug administration
|
|
Incidence of Major Extracranial Bleeding According to ISTH Criteria
Periodo de tiempo: Within 7 days after study drug administration
|
Major extracranial bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as bleeding outside the cranium meeting at least one of the following: fatal bleeding; symptomatic bleeding in a critical extracranial area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome; a decrease in hemoglobin of ≥2 g/dL; or transfusion of ≥2 units of whole blood or red blood cells. |
Within 7 days after study drug administration
|
|
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 5-6
Periodo de tiempo: 90 ± 7 days after randomization
|
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 5-6 indicates severe disability or death. |
90 ± 7 days after randomization
|
|
All-Cause Mortality
Periodo de tiempo: Within 90 days after randomization
|
Within 90 days after randomization
|
|
|
Proportion of Participants Experiencing at Least One Adverse Event
Periodo de tiempo: Within 90 days after study drug administration
|
Within 90 days after study drug administration
|
|
|
Proportion of Participants Experiencing at Least One Serious Adverse Event
Periodo de tiempo: Within 90 days after study drug administration
|
Within 90 days after study drug administration
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: QinJian Sun, Shandong Provincial Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Carrera
- Accidente cerebrovascular isquémico
- Aminoácidos, péptidos y proteínas
- Proteínas
- Terapéutica
- Rutas de administración de drogas
- Terapia con drogas
- Hidrolasas
- Enzimas
- Enzimas y coenzimas
- Proteínas de la sangre
- Endopeptidasas
- Hidrolasas peptídicas
- Serina endopeptidasas
- Serina proteasas
- Activadores de plasminógeno
- Factores de coagulación de sangre
- Activador de plasminógeno tisular
- Tenecteplasa
- Inyecciones
Otros números de identificación del estudio
- SWYX:NO.2026-2023
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .